Featured Articles
-
Ensuring Security And Privacy In Life Sciences Master Data Governance
5/10/2024
High-quality and secure data is the lifeblood of biopharmaceutical innovation and organizational success. Ravikumar Vallepu offers best practices for master data governance plans, and how to cultivate a data-centric culture.
-
The Power of Putting People First in Driving Business Growth
5/7/2024
Happy workers drive high performing businesses. Biopharma executive John Harlow shares five tips for adopting a people-first mindset and other strategies for meaningful engagement with colleagues.
-
Pricing For Rare Disease Therapies And Cures: What’s Fair?
5/6/2024
What is a "fair" price for a curative rare disease therapy, or an effective but chronic rare disease therapy? Charles River Associates surveyed U.S. payers, before and after COVID, to find out.
-
Meaningful Industry Change Means Balancing Tech And Human Touch
5/6/2024
Technology and AI/ML are advancing at an unprecedented pace, and we must not lose sight of our industry's core: human-to-human interaction.
-
Building On Direct-To-Patient Marketing For Improved Access To Therapeutics
5/2/2024
PA Consulting identifies the top three questions that biopharmaceutical companies should consider before launching a direct-to-patient platform and service offering.
-
Where Are They Now? SQZ Biotech
5/1/2024
SQZ Biotech, a novel cell therapy company with Big Pharma backing, is no more. However, the company's science, and its founding CEO, will continue on under new auspices.
-
Take-Home Microdosing Trial Studies Sub-Hallucinogenic For Depression
4/30/2024
MindBio Therapeutics CEO Justin Hanka details the company’s Phase 2a clinical trial investigating the use of a take-home microdosing regimen for depression.
-
Reviva Pharma’s Novel Funding Approach In Schizophrenia
4/25/2024
Reviva Pharma CEO Laxminarayan Bhat, Ph.D. found a novel way to build an investor base for his company during a time when Big Pharma was exiting complicated CNS diseases. Now, Reviva has a late-stage schizophrenia candidate just as CNS is back in vogue.
-
Companies To Watch: OSE Immunotherapeutics
4/22/2024
OSE Immunotherapeutics is poised to begin a confirmatory and pivotal Phase 3 trial for a novel cancer vaccine targeting the second line in NSCLC, an area of acute unmet need.
-
A Deeper Look At What's Driving Dependence On Biotech Contract Manufacturers
4/19/2024
Are you struggling to find CDMO capacity? Here are some of the drivers behind the contract manufacturing market's exponential growth.